navitoclax
AssetSmall moleculeAlso ABT-263
Bcl-2 family protein inhibitor (BCL2, BCL2L1, BCL2L2) that promotes apoptosis.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Apoptosis
- Indications
- 11
- Trials
- 28
- Developers
- 2
Indications
11Myelofibrosis
Phase 3COMPLETEDNCT04472598clinicaltrials.gov7 Oct 2026
Chronic lymphocytic leukemia
Phase 2COMPLETEDNCT01557777clinicaltrials.gov7 Oct 2026
Acute lymphoblastic leukemia
Phase 1COMPLETEDNCT03181126clinicaltrials.gov7 Oct 2026
8 more
- Targets and what it contains5
- Owner and partners2
- Trials28
- Evidence for its targets4
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 8 sources